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RATE-AF trial is the first head-to-head randomized trial of digoxin vs. beta-blockers
in patients with atrial fibrillation and symptoms of heart failure
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The RAte control Therapy Evaluation in permanent Atrial
Fibrillation (RATE-AF) trial was designed as a pragmatic,
healthcare-embedded clinical trial to address the concerns of
patients and improve quality of life.1 With the main results re-
cently published in JAMA,2 RATE-AF has demonstrated how pa-
tient and public involvement (PPI) in trial design and management
can provide new opportunities and generate a robust evidence-
base to guide routine clinical management.
Evidence for a patient and public
involvement approach
‘Research being carried out “with” or “by” members of the public (in-
cluding patients and carers) rather than “to,” “about” or “for” them’ is
the definition of patient and public involvement (www.invo.org.uk).
Using PPI in trial development and management has the potential to
augment patient recruitment in clinical trials, addressing the fact that
one-third of clinical trials fail to reach their recruitment target. In a
meta-analysis of 19 studies including a total of 178 921 participants, 11
out of 21 PPI interventions increased enrolment rates. In the seven
randomized trials, the odds ratio (OR) of a patient enrolling was 1.16
compared to no PPI intervention (95% prediction interval 1.25–2.80;
P¼ 0.04 with no heterogeneity).3 Across all study types, an even more
substantial improvement in recruitment was demonstrated if the PPI
member had the health condition of interest (OR 3.14, 1.89–5.22; vs.
1.07, 0.74–1.53 without the condition).3 Although the authors found
no evidence of significant publication bias, data were insufficient to ad-
dress whether participant retention was improved. Nevertheless, this
adds to growing information that PPI, if properly supported (see
Figure 1) can assist in the deployment of a clinical trial, ethical approval,
avoidance of protocol amendments, enhanced participant adherence,
and lead to reduced cost.4 Patient and public involvement is of particu-
lar importance in data-intensive healthcare research, where informed
consent and privacy are fundamental to good governance and
acceptance by potential participants.5 The ESC is actively involved in
this critical area of big data research (www.escardio.org/bigdata).
Finally, PPI provides a clear route to embedding the patient voice into
clinical research, leading to benefit for all stakeholders.
The RATE-AF trial
The RATE-AF trial was a prospective, randomized, open-label,
blinded endpoint trial addressing a major evidence gap in the man-
agement of AF, the issue of heart rate control.1 Previous studies
were either observational (ignoring the fact that digoxin is often
used as a second-line drug and therefore given to sicker patients6)
or only demonstrating short-term outcomes such as an acute
change in heart rate. In contrast, the RATE-AF trial randomized
patients to either low-dose digoxin or beta-blockers, with out-
comes at 6 and 12 months.1
One hundred and sixty patients aged 60 years or older with perma-
nent AF and at least New York Heart Association Class II dyspnoea
were recruited to the trial, with key findings summarized in Figure 2.
There was no difference in the primary outcome of the physical com-
ponent of quality of life, no difference in long-term heart rate control,
and no deterioration in left ventricular ejection fraction comparing
low-dose digoxin with beta-blockers.
Patients randomized to the digoxin group had significantly better im-
provement in modified European Heart Rhythm Association
(mEHRA) functional class, with 53% reporting a two-class improve-
ment with digoxin at 6 months vs. 9% for beta-blockers (P< 0.001). A
significant reduction in NT-pro-B-type natriuretic peptide at 12-
months was seen in the digoxin group (P¼ 0.005 versus beta-block-
ers), with substantially less adverse events with digoxin compared to
beta-blockers [29 events (25% of patients) vs. 142 events (64% of
patients); P< 0.001]. Many of the patient-reported elements of general
and treatment-specific quality of life also favoured the group random-
ized to digoxin.
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Evolution of RATE-AF with patient
and public involvement
The PPI team made considerable input to the design of the trial; as
advocates for patients with AF, they impressed the importance of pa-
tient well-being as a priority, establishing the primary outcome as the
patient-reported quality of life. The PPI team enhanced recruitment,
for example, by producing a YouTube participant video, and boosted
retention of participants [only three patients (1.9%) in the trial with-
drew]. They also led the development of all patient-facing material, en-
abling clear and explanatory consent forms and information leaflets.
This allowed participants to make truly informed consent and im-
proved their adherence to study medications. Plain English summaries
of the main results have led to dissemination to a wider audience, par-
ticularly for patients with AF in the community and their general practi-
tioners. As members of the Trial Steering Committee, PPI input was
essential for the progress of the trial, such as strategies to accelerate
recruitment and the development of sub-studies. This included em-
bedded studies on (i) wearable devices, where the PPI team helped to
implement technology despite the older population being recruited;
(ii) basic science experiments on cellular and mass-spectrometry end-
points; (iii) imaging studies to improve the reproducibility of echocardi-
ography in AF7; and (iv) PPI-led qualitative studies to understand the
importance of quality of life in the routine clinical assessment of
patients with AF.8
Mary’s viewpoint as a patient on designing
and managing RATE-AF
‘My involvement with the RATE-AF trial began after I was diagnosed
and treated for paroxysmal atrial fibrillation. My fellow PPI team mem-
bers and I have contributed to the design of the study, a successful ap-
plication for funding, trial steering group meetings, and now the final
rewarding results of many years of work. We also led focus groups ex-
ploring quality of life in patients with atrial fibrillation—which we went
on to write up, publish, and present at the International Society of
Quality of Life Research conference where we were awarded Patient
Research Partner Scholarships.
It was these focus groups which gave me the most satisfaction—de-
signing and running them, listening to patients talking about their qual-
ity of life, the neglect they felt at usual health consultations, and the
impact that the trial was having on them. Many patients felt we had
boosted their confidence and ability to self-manage their AF’.
Future perspectives
The involvement of patients, careers, and the public (and indeed any-
one outside the usual clinical-academic framework) has the potential to
improve the basis for clinical trials, support recruitment and retention
of participants, and lead to more robust, and better-targeted evidence
generation. Patient and public involvement is now commonplace in
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stakeholder meetings, the generation of clinical practice guidelines and
efforts at dissemination. Being a mandatory part of developing and man-
aging research studies internationally would seem the next sensible
step to reducing the burden of cardiovascular disease.
On behalf of the RATE-AF Investigators (see Appendix).
Supplementary material
Supplementary material is available at European Heart Journal online.
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